Protalix PB-102-F20: A Randomized, Double blind, Active Control Study of the Safety and Efficacy of PRX-102 compared to Agalsidase Beta on Renal Function in Patients with Fabry Disease Previously Treated With Agalsidase Beta

Project: Research project

Project Details

StatusActive
Effective start/end date5/16/185/15/21

Funding

  • Protalix Ltd.